Biologic agents in the treatment of inflammatory rheumatic diseases

Current Opinion in Rheumatology

Volumn 10, Issue 3, 1998, Pages 174-178

  Kalden, J R ^a   Manger, Bernhard ^a  

^a UNIVERSITY HOSPITAL ERLANGEN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ANTISENSE OLIGODEOXYNUCLEOTIDE; CELL ADHESION MOLECULE; CYCLINE; CYTOKINE; HYBRID PROTEIN; INTERCELLULAR ADHESION MOLECULE 1; INTERLEUKIN 1; METHOTREXATE; MONOCLONAL ANTIBODY; RECOMBINANT GAMMA INTERFERON; RECOMBINANT INTERLEUKIN 10; RECOMBINANT INTERLEUKIN 4; TUMOR NECROSIS FACTOR ALPHA;

DRUG SAFETY; FIBROBLAST; HELPER CELL; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; PRIORITY JOURNAL; RHEUMATIC DISEASE; RHEUMATOID ARTHRITIS; SHORT SURVEY; SIDE EFFECT; TREATMENT OUTCOME;

ANTIBODIES, MONOCLONAL; ANTIGENS, CD4; CLINICAL TRIALS, PHASE III; CYTOKINES; HUMANS; INTERCELLULAR ADHESION MOLECULE-1; INTERLEUKIN-1; RHEUMATIC DISEASES; TUMOR NECROSIS FACTOR-ALPHA;

EID: 0031804935     PISSN: 10408711     EISSN: None     Source Type: Journal    
DOI: 10.1097/00002281-199805000-00004     Document Type: Short Survey

References (28)

1. Morita Y, Kashihara N, Yamamura M, Okamoto H, Harada S, Maeshima Y, Okamoto K, Makino H: Inhibition of rheumatoid synovial fibroblast proliferation by antisense oligonucleotides targeting proliferating cell nuclear antigen messenger RNA. Arthritis Rheum 1997, 40:1292-1297.
2. Cleland LG, Mayrhofer G: Mucosal tolerance and rheumatoid arthritis [editorial]. Br J Rheumatol 1997, 36:1139-1141.
3. Bloemendal A, van der Zee R, Rutten VPMG, van Kooten PJS, Farine JC, van Eden: Experimental Immunization with anti-rheumatic bacterial extract OM-89 induces T cell response to heat shock protein (hsp) 60 and hsp70: modulation of peripheral immunological tolerance as its possible mode of action in the treatment of rheumatoid arthritis (RA). Clin Exp Immunol 1997, 110:72-78. Using an OM-89 bacterial/heat shock protein for patenteral immunization, it was found that the resistance to adjuvant arthritis was reduced, whereas oral administration of OM-89 was described as protective. This paper reports new and exciting data indicating that heat shock proteins might be used to modulate peripheral immunologic tolerance as a possible treatment strategy of rheumatoid arthritis.
4. Mojcik CF, Shevach EM: Adhesion molecules: a rheumatologic perspective [review]. Arthritis Rheum 1997, 40:991-1004.
5. Isaacs JD: Immunoadhesins for immunomodulation of autoimmune and rheumatic disease [editorials]. Br J Rheumatol 1997, 36:305-307.
6. Kavanaugh AF, Schulze-Koops H, Davis LS, Lipsky PE: Repeat treatment of rheumatoid arthritis patients with a murine anti-intercellular adhesion molecule 1 monoclonal antibody. Arthritis Rheum 1997, 40:849-853. Repeated courses of therapy with a monoclonal antibody to the adhesion molecule ICAM-1 turned out not to be useful in the treatment of rheumatoid arthritis. Besides major side effects probably caused by the immunogenicity of the monoclonal antibody, clinical efficacy was less than that observed after the first course.
7. Kalden JR, Manger B: Biologic agents in the treatment of inflammatory rheumatic diseases. Curr Opin Rheumatol 1997, 9:206-212.
8. V.
9. Fox DA: Review: the role of T cells in the immunopathogenesis of rheumatoid arthritis. Arthritis Rheum 1997, 40:598-609.
10. Isaacs JD, Burrows N, Wing M, Keogan MT, Rebello PRUB, Watts RA, Pye RJ, Norris P, Hazelman BL, Hale G, Waldmann H: Humanized anti-CD4 monoclonal antibody therapy of autoimmune and inflammatory disease. Clin Exp Immunol 1997, 110:158-166.
11. Tesser JRP, Wiesenhutter C, Levy R, Schiff M, Lipani J, Solinger A, Mac Donald B, Elliott M, Sing K: Treatment of rheumatoid arthritis with a primatized anti-CD4 monoclonal antibody, SB-210396 (DEC-CE9, 1): results of an open label extension study in patients responding to induction therapy. Arthritis Rheum 1997, 40(suppl 9):S224.
12. Choy EHS, Conolly DJA, Rapson N, Kingles GH, Johnston JM, Panayi GS: Effect of a humanised non-depleting anti-CD4 monoclonal antibody (mAb) on synovial fluid (SF) in rheumatoid arthritis (RA). Arthritis Rheum 1997, 40(suppl 9):S52.
13. Reece RJ, Veale DJ, Orgles CS, Radjenovic A, O'Connor PJ, Ridgeway J, Boylston AW, Gibbon W, Emmery P: Intra-articular injection of the knee with human anti-CD4 monoclonal antibody in rheumatoid arthritis: an arthroscopic and magnetic resonance study of efficacy and safety. Br J Rheumatol 1997, 36(suppl 1):S188.
14. Morgan AW, Hale G, Waldmann H, Emery P, Isaacs JD: Combination of anti-cytokine and anti-T-cell therapy for rheumatoid arthritis: a pilot study. Br J Rheumatol 1997, 36(suppl 1):S106.
15. Moreland L, Koopman WJ, Adamson T, Calabrese L, Cash J, Markenson J, Matsumoto A, Matteson E, Weyand C, Carlo D, et al.: Results of phase II rheumatoid arthritis clinical trial using T cell receptor peptides. Arthritis Rheum 1997, 40(suppl 9):S223.
16. St. Clair WE, Cohen SB, Fleischmann RM, Le S, Moreland L, Olsen NJ, Pratt PW, Yocum DE, Winkelhake J, Holcenberg J, Shulman MG: Vaccination of rheumatoid arthritis (RA) patients with DR4/1-peptide. Arthritis Rheum 1997, 40(suppl 9):S96.
17. Moreland LW, Baumgartner SW, Schiff MH, Tindall EA, Fleischmann RM, Weaver AL, Ettlinger RE, Cohen S, Koopman WJ, Mohler K, et al.: Treatment of rheumatoid arthritis with a recombinant human tumor necrosis factor receptor (p75)-Fc fusion protein. N Engl J Med 1997, 337:141-147. This communication must be regarded as a landmark in the development of new treatment principles for rheumatoid arthritis, using a recombinant human TNF receptor fusion protein. In a 3-month trial TNFRp75:Fc was shown to be safe and well tolerated and was associated with a significant improvement in the inflammatory symptoms of rheumatoid arthritis patients.
18. Mohler K, Torrance D, Otten C, Widmer M: TNF neutralizing capacity of human p55 and p75 TNF receptor Fc fusion proteins. Arthritis Rheum 1997, 40(suppl 9):S80.
19. Chatham WW, McDuffie D, Zhang L, Blackburn W: Effects of rhuTNFR:Fc on neutrophil function. Arthritis Rheum 1997, 40(suppl 9):S81.
20. Maini RN, Breedveld FC, Kalden JR, Smolen JS, Davis D, MacFarlane JD, Antoni C, Leeb B, Elliott MJ, Woody JN, et al.: Low dose methotrexate (MTX) suppresses anti-globulin responses and potentiates efficacy of a chimeric monoclonal anti-TNF-alpha antibody (cA2) given repeatedly in rheumatoid arthritis (RA). Arthritis Rheum 1997, 40(suppl 9):S126. Important data demonstrating that combination therapy with the anti-TNF-α monoclonal antibody cA2 and methotrexate suppressed the antiglobulin response and potentiated the efficacy of the monoclonal antibody when given repeatedly.
21. Brennan FM, Browne KA, Green PA, Jaspar JM, Maini RN, Feldmann M: Reduction of serum matrix metalloproteinase 1 and matrix metalloproteinase 3 in rheumatoid arthritis patients following anti-tumor necrosis factor-alpha (cA2) therapy. Br J Rheumatol 1997, 36:643-650. Interesting data on the mode of action of the anti-TNF-α monoclonal antibody cA2. This study confirms previous reports demonstrating that MMP-3 levels are elevated and correlate with acute-phase reactants of inflammation in rheumatoid arthritis and that serum MMP-3 and MMP-1 levels are downmodulated following anti-TNF-α antibody therapy.
22. Taylor PC, Chapman P, Elliott MJ, Schaible TF, Peters AM, Feldman M, Maini RN: Reduced granulocyte traffic and chemotactic gradients in rheumatoid joints following anti-TNF-alpha therapy. Arthritis Rheum 1997, 40(suppl 9):S80.
23. Davis D, Charles PJ, Potter A, Feldmann M, Maini RN, Elliott MJ: Anaemia of chronic disease in rheumatoid arthritis: in vivo effects of tumor necrosis factor alpha blockade. Br J Rheumatol 1997, 36:950-956. An interesting observation indicating that anemia of chronic disease in rheumatoid arthritis is caused by TNF-α, possibly by a direct action on erythroid precursors. Anemia of chronic disease in rheumatoid arthritis improved after cA2 treatment, and data are shown suggesting a mechanism independent of erythropoietin suppression.
24. Cibere J, Sibley J, Haga M: Rheumatoid arthritis and the risk of malignancy. Arthritis Rheum 1997, 40:1580-1586. A comprehensive review on the risk of malignancy in rheumatoid arthritis. An increased risk of hemopoietic malignancies was confirmed: however, despite the treatment of rheumatoid arthritis patients with potentially oncogenic agents, the overall risk of malignancy was reduced in the cohort of rheumatoid arthritis patient studied. This communication is of special interest with regard to the reported incidence of lymphomas in patients receiving biologic agents.
25. Veys EM, Menkes CJ, Emery P: A randomized, double-blind study comparing twenty-four-week treatment with recombinant interferon-gamma versus placebo in the treatment of rheumatoid arthritis. Arthritis Rheum 1997, 40:62-68.
26. Joosten LA, Lubberts E, Durez P, Helsen MM, Jacobs MJ, Goldman M, van den Berg WB: Role of interleukin-4 and interleukin-10 in murine collagen-induced arthritis: protective effect of interleukin-4 and interleukin-10 treatment on cartilage destruction. Arthritis Rheum 1997, 40:249-260. An interesting communication about the role of pro- and anti-inflammatory cytokines on cartilage destruction. The dominant role of interleukin-10 in the natural suppression of arthritis was described. The combination treatment of interleukin-10 with interleukin-4 appeared of potential therapeutic value, not only at the onset but also in established experimental arthritis.
27. Maini RN, Breedveld FC, Moreland LW, St. Clair EW, Russell AS, Charles P, Davies D, Grint P, Wherry JC, Feldmann M: rHUIL-10 in subjects with active rheumatoid arthritis (RA): a phase I and cytokine response Study. Arthritis Rheum 1997, 40(suppl 9):S224.
28. Müller-Ladner U, Roberts CR, Franklin BN, Gay RE, Robbins PD, Evans CH, Gay S: Human IL-1 Ra gene transfer into human synovial fibroblasts is chondroprotective. J Immunol 1997, 158:3492-3498. A new and interesting gene therapeutic approach underscoring first that interleukin-β is an important proinflammatory cytokine involved in chondrocyte destruction, and second that an overexpression of interleukin-1 receptor antagonist might have a significant protective effect.